Barclays analyst Carter Gould lowered the firm’s price target on Merck to $140 from $142 and keeps an Overweight rating on the shares as part of an earnings preview for the biopharmaceutical group. The firm sees a challenging large-cap biopharma setup for Q3.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- Trump backs off support of controversial drug pricing plan, STAT reports
- Merus price target raised to $111 from $93 at Guggenheim
- Merck completes acquisition of CN201 from Curon
- Evaxion Biotech deal underscores potential of AI models, says H.C. Wainwright
- Evaxion Biotech expands vaccine development collab with Merck